Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy

Completed · Phase 4

Conditions studied: Acute Decompensated Heart Failure

In brief

The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.

Key facts

Study ID

NCT00842023

Run by

Western University of Health Sciences

People needed

89

Starts

2006-07-01

Expected to finish

2009-02-01

Last updated by the study team

2013-08-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age.
• Subject must be able to understand the potential risks and benefits associated with the study.
• Baseline systolic blood pressure ≥ 90 mm Hg at the time of enrollment.
• Clinical symptoms of dyspnea and laboratory admission BNP levels > 500 pg/mL.
• Neither pregnant or breastfeeding at the time of enrollment.
• Authorization of patient's enrollment by patient's medical provider.

You may not qualify if…

• <18 years of age
• Denies written informed consent
• Pregnant or lactating.
• Baseline systolic BP < 90 mmHg or cardiogenic shock
• No symptoms of congestion or admission BNP < 500 pg/mL
• Known allergy to E.coli-derived products, or any history of anaphylactic reactions to nesiritide.
• Receiving dialysis at the time of enrollment.
• Serum creatinine > 2.5 mg/dL at the time of enrollment.

Where it is running

• Centinela Hospital Medical Center — Inglewood, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.